Department of Surgery, Division of Endovascular and Vascular Surgery, Brigham & Women's Hospital and Harvard Medical School, Boston, Mass; Department of Surgery, Division of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Center for Surgery and Public Health, Department of Surgery, Brigham & Women's Hospital, Boston, Mass.
J Vasc Surg. 2014 May;59(5):1315-22.e1. doi: 10.1016/j.jvs.2013.11.059. Epub 2014 Jan 11.
The value and cost-effectiveness of less invasive alternative imaging (AI) modalities (duplex ultrasound scanning, computed tomography angiography, and magnetic resonance angiography) in the care of peripheral arterial disease (PAD) has been reported; however, there is no consensus on their role. We hypothesized that AI utilization is low compared with angiography in the United States and that patient and hospital characteristics are both associated with AI utilization.
The Nationwide Inpatient Sample (2007-2010) was used to identify patients with an International Classification of Diseases-Ninth Edition diagnosis of claudication or critical limb ischemia (CLI) as well as PAD treatment (surgical, endovascular, or amputation). Patients with AI and those with angiography or expected angiography (endovascular procedures without imaging codes) were selected and compared. Multivariable logistic regression was performed for receiving AI stratified by claudication and CLI and adjusting for patient and hospital factors.
We identified 290,184 PAD patients, of whom 5702 (2.0%) received AI. Patients with AI were more likely to have diagnosis of CLI (78.8% vs 48.6%; P < .0001) and receive open revascularizations (30.4% vs 18.8%; P < .0001). Van Walraven comorbidity scores (mean [standard error] 5.85 ± 0.22 vs 4.10 ± 0.05; P < .0001) reflected a higher comorbidity burden in AI patients. In multivariable analysis for claudicant patients, AI was associated with large bed size (odds ratio [OR], 3.26, 95% confidence interval [CI], 1.16-9.18; P = .025), teaching hospitals (OR, 1.97; 95% CI, 1.10-3.52; P = .023), and renal failure (OR, 1.52; 95% CI, 1.13-2.05; P = .006). For CLI patients, AI was associated with black race (OR, 1.53; 95% CI, 1.13-2.08; P = .006) and chronic heart failure (OR, 1.29; 95% CI, 1.04-1.60; P = .021) and was negatively associated with renal failure (OR, 0.80; 95% CI, 0.67-0.95; P = .012). The Northeast and West regions were associated with higher odds of AI in claudicant patients (OR, 2.41; 95% CI, 1.23-4.75; P = .011; and OR, 2.59; 95% CI, 1.34-5.02; P = .005, respectively) and CLI patients (OR, 4.31; 95% CI, 2.20-8.36; P < .0001; and OR, 2.18; 95% CI, 1.12-4.22; P = .021, respectively). Rates of AI utilization across states were not evenly distributed but showed great variability, with ranges from 0.31% to 9.81%.
National utilization of AI for PAD is low and shows great variation among institutions in the United States. Patient and hospital factors are both associated with receiving AI in PAD care, and AI utilization is subject to significant regional variation. These findings suggest differences in systems of care or practice patterns and call for a clearer understanding and a more unified approach to imaging strategies in PAD care.
已经有研究报告称,在周围动脉疾病(PAD)的治疗中,微创替代成像(AI)方式(双功能超声扫描、计算机断层血管造影和磁共振血管造影)的价值和成本效益。然而,对于其作用尚未达成共识。我们假设与血管造影相比,美国的 AI 利用率较低,并且患者和医院的特征都与 AI 的使用有关。
利用全国住院患者样本(2007-2010 年),确定国际疾病分类第九版诊断为跛行或临界肢体缺血(CLI)以及 PAD 治疗(手术、血管内或截肢)的患者。选择并比较了 AI 和血管造影或预期血管造影(无血管成像代码的血管内程序)的患者。对跛行和 CLI 患者分层,按 AI 进行多变量逻辑回归,同时调整患者和医院因素。
我们确定了 290184 例 PAD 患者,其中 5702 例(2.0%)接受了 AI。接受 AI 的患者更可能患有 CLI(78.8%比 48.6%;P <.0001)和接受开放血管重建术(30.4%比 18.8%;P <.0001)。Van Walraven 合并症评分(平均[标准误差]5.85 ± 0.22 比 4.10 ± 0.05;P <.0001)反映了 AI 患者更高的合并症负担。在跛行患者的多变量分析中,AI 与床位大(比值比[OR],3.26,95%置信区间[CI],1.16-9.18;P =.025)、教学医院(OR,1.97;95% CI,1.10-3.52;P =.023)和肾功能衰竭(OR,1.52;95% CI,1.13-2.05;P =.006)相关。对于 CLI 患者,AI 与黑人种族(OR,1.53;95% CI,1.13-2.08;P =.006)和慢性心力衰竭(OR,1.29;95% CI,1.04-1.60;P =.021)相关,与肾功能衰竭(OR,0.80;95% CI,0.67-0.95;P =.012)呈负相关。东北地区和西部地区与跛行患者的 AI 更高几率相关(OR,2.41;95% CI,1.23-4.75;P =.011;和 OR,2.59;95% CI,1.34-5.02;P =.005,分别)和 CLI 患者(OR,4.31;95% CI,2.20-8.36;P <.0001;和 OR,2.18;95% CI,1.12-4.22;P =.021,分别)。各州的 AI 利用率分布不均,差异很大,范围从 0.31%到 9.81%。
美国 AI 在 PAD 中的应用率较低,且在美国各医疗机构之间存在很大差异。患者和医院的特征都与 PAD 护理中接受 AI 有关,AI 的应用受到显著的区域差异的影响。这些发现表明存在护理系统或实践模式的差异,并呼吁对 PAD 护理中的成像策略有更清晰的理解和更统一的方法。